Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Roivant

Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug

Roivant Sciences is making serious changes to subsidiary Immunovant, announcing Monday a series of C-suite changes and new disease targets.

Investors Business Daily

Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

Investors Business Daily

The 'Extremely Positive' Results That Helped Roivant Leapfrog Its 50-Day Line, Nearing A Breakout

Roivant stock is nearing a breakout Tuesday after the company announced positive results in an eye-disease study and a $1.5 billion buyback.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Roche Follows Merck, Sanofi Into A Red-Hot Immunology Space With A $7.1 Billion Buyout

Roche said Monday it would buy an experimental immunology drug from Roivant and Pfizer for $7.1 billion. But ROIV stock sank.

Investors Business Daily

Vivek Ramaswamy is furiously defending his business ties in China. What are they?

‘Vivek’s first business had a subsidiary in China’ which was closed ‘as the risks of doing business in China became apparent,’ Ramaswamy spokesperson says

The Independent UK

Smoke and mirrors: I’ve been debating Vivek Ramaswamy for 2 years. Here’s how I got past his diversionary tactics

Vivek Ramaswamy's fiercest critic, Yale Professor Jeffrey Sonnenfeld, has studied the presidential hopeful's debate strategies–and his business record.

Fortune

Vivek Ramaswamy: The mini Trump making waves in the Republican contest

Broadly viewed as the winner of the Republican presidential debate, the ‘anti-woke’ tech bro has broken out from the GOP pack

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

‘He’s an insider’: Ramaswamy’s deep ties to rightwing kingpins revealed

Republican candidate brands himself as an ‘outsider’ but has close links to prominent figures Leonard Leo and Peter Thiel

The Guardian - US

How Vivek Ramaswamy, the surprise GOP debate star, made his fortune and triggered his critics

He bills himself as an iconoclast ready to shake up the Republican Party after making millions trying to do the same in the biotech industry.

Fortune

Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales

Biotech stock Roivant — founded by presidential candidate Vivek Ramaswamy — reported steep losses and lighter sales.

Investors Business Daily

Roche Could Take A Page Out Of Merck's Playbook. Why Roivant Surged.

Roche is in discussions to buy a stomach-disease treatment from Roivant for around $7 billion. The report sent ROIV stock surging Friday.

Investors Business Daily

A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout

Roivant said Thursday more than a third of ulcerative colitis patients entered remission in its study. ROIV stock hit a buy point on the news.

Investors Business Daily

Vivek Ramaswamy is threatening GOP heavyweights in the polls–but his business record doesn't live up to the hype

Yale's Sonnenfeld and Tian retrace presidential hopeful Vivek Ramaswamy's business record.

Fortune

Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom

Merck is acquiring Prometheus Bio in a well-timed $10.8 billion deal ahead of Keytruda's patent loss. The news sent RXDX stock flying Monday.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Roivant, Pfizer Unveil Latest Spinout Focused On Autoimmune Diseases

Roivant Sciences Ltd (NASDAQ:ROIV) and Pfizer Inc (NYSE:PFE) unveiled Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases. Priovant was established in September 2021 through a transaction between Roivant and Pfizer. Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25%…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.